Phase II study of imatinib mesylate in patients with life threatening malignant rare diseases.
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2012
At a glance
- Drugs Imatinib (Primary)
- Indications Cancer; Dermatofibrosarcoma
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 19 Apr 2012 Actual end date (1 Jan 2007) added as reported by ClinicalTrials.gov.
- 07 Sep 2007 Status changed from in progress to completed
- 11 Dec 2005 New trial record.